Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Aug 15, 2019; 11(8): 634-641
Published online Aug 15, 2019. doi: 10.4251/wjgo.v11.i8.634
Published online Aug 15, 2019. doi: 10.4251/wjgo.v11.i8.634
Table 3 Serious adverse events during perioperative time (n = 33)
| Patients with at least one grade 3-4 adverse event during perioperative time | 6 (18) |
| Medical complication | 7 (21) |
| Anastomotic leak | 2 (6) |
| Wound healing disorder | 1 (3) |
| Pneumonia | 7 (21) |
| Pleural complication | 1 (3) |
| Sepsis and infection | 5 (15) |
| Intestinal occlusion | 2 (6) |
| Bleeding | 1 |
- Citation: Basso V, Orry D, Fraisse J, Vincent J, Hennequin A, Bengrine L, Ghiringhelli F. Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study. World J Gastrointest Oncol 2019; 11(8): 634-641
- URL: https://www.wjgnet.com/1948-5204/full/v11/i8/634.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i8.634